Sarepta shares sink as FDA staff stay sour on muscle disorder drug

April 21 (Reuters) - Sarepta Therapeutics Inc lost

more than a third of its market value after U.S. Food and

Administration staff maintained their negative outlook on the

company's rare muscle...

Read more